About Us
Our belief in domestic sterile manufacturing isn’t new - it’s proven. From a COVID-era FDA approval in New York to a new injectables plant in New Jersey, we're building the future stateside
RK Pharma Journey
API & Intermediates
-
Peptides
-
Advanced intermediates
-
Complex APIs
-
Sterile APIs
-
Peptides
-
Injectables - Solutions, Suspensions, Nano-suspensions
-
Long Acting Injectables
-
Sterile Ophthalmics
-
Pens & Auto-injectors
Drug Products
2003 - 2015
-
Company Apicore established
-
Focus on manufacturing API & Intermediates
2017
-
Mylan acquired a basket of products for $210 Mn
-
50 DMFs and 17 ANDAs
2020
-
Sterile drug manufacturing at Pearl River, NY, USA
2024
From molecules to medicine - since 2003, RK Pharma has evolved from a trusted manufacturer of APIs and intermediates to finished drug products
With strategic funding and new manufacturing facilities, we are now poised to deliver patient-ready solutions like pre-filled syringes
-
Received additional funding from PAG
-
Started setting up new injectables facility at East Windsor, NJ
-
Filed several ANDAs/NDAs and EU Dossiers
At a Glance
We believed in bringing sterile manufacturing stateside, and since 2019, we've backed that belief with action.
From securing and fast-tracking FDA approval for our New York facility in just two years during COVID, to now building our next-gen injectables plant in New Jersey, we're not waiting for the shift, we're leading it
-
Well-funded US-based pharma CDMO specializing in sterile injectables
-
FDA-approved and partner-trusted with over 25 successful FDA audits and a gold standard in compliance
-
Delivering end-to-end manufacturing solutions for over 25 years from clinical trials to large-scale commercial production
-
2 state-of-the-art manufacturing facilities for aseptic fill-finish, lyophilization, and high-potency containment
Meet the Team
Dr. Ravishanker Kovi
Executive Chairman & Director
20+ years of experience in medicinal/ organic chemistry, clinical and pre-clinical PK/PD and drug metabolism, QC/QA and Regulatory Affairs.
Dr. George R. Thomas
President & CEO, Director
20+ years of experience in New Drug Development and Generic Pharmaceutical Industry
Mr. Samit Deb
Manufacturing Head
20+ years of experience with manufacturing startups, regulatory filings, hosting regulatory inspections, commercialization of generic products and supply chain management.